ClinicalTrials.gg
DrugBiological

Talimogene laherparepvec clinical trials

Also written Imlygic, JS1 34.5-hGMCSF 47- pA- and ICP34.5-, ICP47-deleted Herpes Simplex Virus 1 (HSV-1) Incorporating the Human GM-CSF Gene.

studies test it
43
open now
2
in phase 3
4
first study started
2005

How each study uses talimogene laherparepvec is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the talimogene laherparepvec studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
27 Oct 2015 · Imlygic · BLA 125518 (FDA, Purple Book)
European Union
16 Dec 2015 · Imlygic · EMEA/H/C/002771 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Talimogene Laherparepvec
35
T-VEC
20
OncoVEX^GM-CSF
9
Talimogene Laherparepvec (T-VEC)
3
TALIMOGENE LAHERPAREPVEC (TVEC)
2

Brand

Imlygic
26
OncoVex
1

Development codes

JS1 34.5-hGMCSF 47- pA-
8

Other names

ICP34.5-, ICP47-deleted Herpes Simplex Virus 1 (HSV-1) Incorporating the Human GM-CSF Gene
8

Studies by the year they started

43 studies that test it; most in 2019 (8)

Studies that test talimogene laherparepvec, by start year
YearStudies
20051
20061
20081
20091
20101
20111
20131
20142
20153
20164
20176
20185
20198
20205
20211
20251
20261

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
19
Phase 2
26
Phase 3
4

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 17 · Other 26

Amgen (11) · BioVex Limited (6) · National Cancer Institute (NCI) (4) · John Rieth (2) · Memorial Sloan Kettering Cancer Center (2) · H. Lee Moffitt Cancer Center and Research Institute (2) · SOLTI Breast Cancer Research Group (1) · The Netherlands Cancer Institute (1)

Often tested with

Tested in the same studies.

Pembrolizumab (5) · Nivolumab (4) · Atezolizumab (2) · Panitumumab (1) · Ipilimumab (1) · Trametinib (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 3

Studies that test talimogene laherparepvec.

Studies

Open first, then newest update. How each study uses talimogene laherparepvec is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 43

See all 43 studies that test talimogene laherparepvec →

Given beside what is tested · 3 — talimogene laherparepvec is usual care or a partner of the new treatment

Codes

What other systems call talimogene laherparepvec · ClinicalTrials.gg INT001044

  • MeSH (NLM) C000629782talimogene laherparepvecConfirmed ClinicalTrials.gov, Wikidata
  • UNII (FDA) 07730V90L6TALIMOGENE LAHERPAREPVECConfirmed FDA, Wikidata
  • RxNorm 1721264Confirmed FDA, Wikidata
  • Wikidata Q7679524talimogene laherparepvecConfirmed FDA, Wikidata
  • NCI Thesaurus C61314Talimogene LaherparepvecOne source FDA
  • DrugBank DB13896One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.